Status:
SUSPENDED
Proactive Care of Ambulatory COVID19 Patients
Lead Sponsor:
Centre Hospitalier Universitaire, Amiens
Conditions:
Covid19
Azithromycin
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
On January 9, 2020, a new emerging virus was identified by WHO as being responsible for grouped cases of pneumonia in China. It is a coronavirus, SARS-CoV-2, responsible for the disease COVID-19 (Coro...
Detailed Description
On January 9, 2020, a new emerging virus was identified by WHO as being responsible for grouped cases of pneumonia in China. It is a coronavirus, SARS-CoV-2, responsible for the disease COVID-19 (Coro...
Eligibility Criteria
Inclusion
- Patients treated at the CHU Amiens Picardie presenting:
- Age ≥18 years
- Showing symptoms of COVID -19 and a positive RT-PCR by nasopharyngeal swab
- Non-severe patient, outpatient (not hospitalized), without oxygen
- Having signed a consent to participate in the study
Exclusion
- Patient with a contraindication to taking azithromycin, namely: Allergy to macrolides, Severe liver failure.
- In combination with medicines containing cisapride, colchicine, ergotamine or dihydroergotamine
- Pregnant, parturient or breastfeeding women.
- Asymptomatic patients
- Patient unable to be compliant with study protocol
- Patient under guardianship or curators, under the protection of justice or private public law.
Key Trial Info
Start Date :
April 29 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2023
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT04371107
Start Date
April 29 2020
End Date
July 1 2023
Last Update
March 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Amiens
Amiens, France, 80480